Leerink Partnrs Has Bearish Outlook for ORKA FY2024 Earnings

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Equities researchers at Leerink Partnrs lowered their FY2024 EPS estimates for Oruka Therapeutics in a research note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings per share of ($1.56) for the year, down from their previous estimate of ($1.33). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($2.50) per share. Leerink Partnrs also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.31) EPS, Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($1.59) EPS, FY2026 earnings at ($1.96) EPS and FY2027 earnings at ($1.99) EPS.

Several other analysts have also issued reports on the company. Stifel Nicolaus started coverage on Oruka Therapeutics in a report on Friday, October 11th. They set a “buy” rating and a $49.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $45.00 price objective on shares of Oruka Therapeutics in a research note on Thursday, October 31st. Jefferies Financial Group started coverage on shares of Oruka Therapeutics in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 target price for the company. Lifesci Capital began coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They set an “outperform” rating and a $41.00 price target for the company. Finally, TD Cowen initiated coverage on shares of Oruka Therapeutics in a research note on Monday, September 16th. They issued a “buy” rating on the stock. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Oruka Therapeutics presently has an average rating of “Buy” and an average price target of $43.17.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock opened at $21.13 on Monday. The company has a market cap of $25.53 million, a price-to-earnings ratio of -3.38 and a beta of 0.87. The business’s fifty day moving average is $26.76. Oruka Therapeutics has a one year low of $18.72 and a one year high of $53.88.

Institutional Investors Weigh In On Oruka Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ORKA. The Manufacturers Life Insurance Company bought a new position in Oruka Therapeutics in the 3rd quarter valued at approximately $1,037,000. FMR LLC acquired a new position in shares of Oruka Therapeutics during the third quarter worth $114,763,000. Great Point Partners LLC acquired a new position in shares of Oruka Therapeutics during the third quarter worth $12,614,000. Braidwell LP bought a new position in shares of Oruka Therapeutics in the 3rd quarter valued at $12,640,000. Finally, Janus Henderson Group PLC acquired a new stake in shares of Oruka Therapeutics during the 3rd quarter valued at $5,840,000. 56.44% of the stock is owned by institutional investors.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.